Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-859-8 | CAS number: 14024-61-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In an OECD Test Guideline 425 study, to GLP, the acute oral LD50 value of palladium di(4-oxopent-2-en-2-oate) was estimated to be 2000 mg/kg bw (Matting, 2013).
In a limit test conducted according to OECD Test Guideline 402, and to GLP, the acute dermal LD50 in rats of palladium di(4-oxopent-2-en-2-oate) following 24-hr skin contact was more than 2000 mg/kg bw (Matting, 2014).
No relevant acute inhalation toxicity data were identified.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 27 August to 23 October 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: OECD guideline study, to GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 425 (Acute Oral Toxicity: Up-and-Down Procedure)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- up-and-down procedure
- Limit test:
- no
- Species:
- rat
- Strain:
- other: RccHan:(WIST)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories S.r.l., S.Pietro al Natisone (UD), Zona Industriale Azzida, 57, 33040, Italy
- Age at study initiation: ~9-12 weeks
- Weight at study initiation: 166-203 g
- Fasting period before study: overnight
- Housing: individual caging (polypropylene/polycarbonate)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.2-24.7
- Humidity (%): 31-70
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: Reception from: 21 August to 18 September 2013. Necrospy from: 10 September to 23 October 2013 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- distilled
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: various
- Amount of vehicle (if gavage): various
- Justification for choice of vehicle: commonly used solvent
MAXIMUM DOSE VOLUME APPLIED: 10 ml/kg bw (1.7-2.0 ml/animal)
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: LD50 expected to be between 300 and 2000 mg/kg bw - Doses:
- 550 or 2000 mg/kg bw
- No. of animals per sex per dose:
- 550 mg/kg bw: 2 females
2000 mg/kg bw: 5 females - Control animals:
- other: not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: checked for clinical signs at 30 minutes, then 1, 2, 3, 4 and 6 hours after dosing. Then checked once daily for 14 days. Body weight measured on days -1, 0 (start of experiment), 7 and 14. Body weight of dead animals recorded at necropsy.
- Necropsy of survivors performed: yes (gross pathology of the cranial, thoracic and abdominal cavities) - Statistics:
- Not relevant
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks:
- mortality
- Remarks on result:
- other: CL not determined.
- Mortality:
- Mortality was observed on days 1 and 12 in 2/5 animals receiving a single dose of palladium di(4-oxopent-2-en-2-oate) at 2000 mg/kg bw. No mortality was observed in the 2 animals treated with 550 mg/kg bw. See Table 1 in "any other information on results incl. tables" for details.
- Clinical signs:
- other: At 550 mg/kg bw, decreased activity and decreased general body tone was observed in one animal on days 2-5. The other animal remained symptom-free throughout the observation period. At 2000 mg/kg bw, the test item caused decreased activity, hunched back
- Gross pathology:
- Animals found dead:
Dark/red foci, found at the glandular mucosa of the stomach in 2/2 rats which were found dead, were considered to be potentially related to the administration of the test item. Other changes such as collapsed/non-collapsed lungs, dilatation of the stomach with gas, or clear liquid at the perinasal fur were regarded as agonal or post mortem.
Surviving animals (necropsy at day 14):
There were no macroscopic abnormalities in animals dosed at 550 mg/kg bw or in surviving rats dosed at 2000 mg/kg bw and terminated on Day 14. - Other findings:
- No data
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- In an acute oral toxicity test (up and down procedure) on female rats, conducted to GLP and according to OECD Test Guideline 425, the LD50 for palladium di(4-oxopent-2-en-2-oate) was estimated to be 2000 mg/kg bw.
- Executive summary:
The acute oral toxicity of palladium (II) di(4-oxopent-2-en-2-oate) was assessed using the up and down procedure. The study was performed to GLP and according to OECD Test Guideline 425.
Female RccHan:(WIST) rats were treated with a single oral (gavage) dose of the test material (in distilled water) at 550 mg/kg bw (2 animals) or 2000 mg/kg bw (5 animals), before a 14-day observation period. Animals were checked for clinical signs of toxicity, and effects on body weight. Rats were subject to gross necropsy upon death or terminal killing.
Two of the five animals treated with 2000 mg/kg bw died, while neither of the two animals treated with 550 mg/kg bw died. Under the conditions of this study, the acute oral LD50 was estimated to be about 2000 mg/kg bw in female rats. The test compound would therefore be cautiously classified as Category 4 for acute toxicity via the oral route under the EU CLP regulation.
Reference
Table 1. Mortality of animals treated via gavage with palladium di(4-oxopent-2-en-2-oate)
Animal Number |
Dosage (mg/kg bw) |
Dose volume (ml/animal) |
Viability/Mortality |
|
Short term |
Long term |
|||
2903 |
550 |
1.7 |
Survived |
Survived |
2904 |
2000 |
1.9 |
Survived |
Survived |
2905 |
2000 |
1.9 |
Died |
- |
2906 |
550 |
2.0 |
Survived |
Survived |
3477 |
2000 |
1.7 |
Survived |
Died |
3478 |
2000 |
1.9 |
Survived |
Survived |
3479 |
2000 |
2.0 |
Survived |
Survived |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Overall, good-quality database which meets REACH Standard Information Requirements.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 18 February to 6 March 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study performed to GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories S.r.l., S.Pietro al Natisone (UD), Zona Industriale Azzida, 57, 33040, Italy
- Age at study initiation: "Young adult rats"
- Weight at study initiation: 200-254 g
- Fasting period before study: No data
- Housing: Individually in polypropylene/polycarbonate cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.4-22.7
- Humidity (%): 31-45%
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 12 February 2014 To: 4-6 March 2014 - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: No data
- % coverage: About 10%
- Type of wrap if used: Sterile gauze pad covered in a patch with an adhesive hypoallergenic plaster. The entire trunk of the animal was wrapped in a semi-occlusive plastic wrap
REMOVAL OF TEST SUBSTANCE
- Washing (if done): With water (at body temperature) at the end of the exposure period
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw
- Constant volume or concentration used: No data
- For solids, paste formed: Dampened with water - Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- not required
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations at 1 and 5 hours after treatment, then once daily. Body weight recorded just before treatment (day 0) and on study days 7 and 14.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, skin irritation, body weight - Statistics:
- Not performed
- Preliminary study:
- Not performed
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortalities seen
- Mortality:
- No deaths were seen.
- Clinical signs:
- other: At 2000 mg/kg bw, the test item caused slightly decreased activity and a hunched back in four animals (2 females and 2 males) and piloerection in one male. All animals were symptom free from 10 days after the treatment until the end of the observation per
- Gross pathology:
- No adverse findings observed.
- Other findings:
- - Other observations: Yellowish staining was observed on the treated skin in all animals after treatment.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- In a limit test conducted according to OECD Test Guideline 402, and to GLP, the acute dermal LD50 in rats of palladium di(4-oxopent-2-en-2-oate) following 24-hr skin contact was more than 2000 mg/kg bw .
- Executive summary:
In a limit test performed in accordance with OECD Test Guideline 402 and to GLP, young Wistar rats (5/sex) were given a 24-hour semi-occlusive application of palladium di(4-oxopen-2-en-2-oate) at 2000 mg/kg bw (dampened with water to ensure good contact with the skin). Animals were observed for 14 days after treatment for deaths, as well as changes in body weight and clinical signs of toxicity. At necropsy, any gross abnormalities were reported.
No deaths were seen over the 14-day observation period; the acute dermal LD50 was determined to be more than 2000 mg/kg bw. Based on the results of this study, classification for acute dermal toxicity under the EU CLP regulation would not be required for the test compound.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- Overall, good-quality database which meets REACH Standard Information Requirements.
Additional information
No relevant acute toxicity human data were identified.
The acute oral toxicity of palladium di(4-oxopent-2-en-2-oate) was assessed using the up and down procedure. The study was performed to GLP and according to OECD Test Guideline 425. Female RccHan:(WIST) rats were treated with a single oral (gavage) dose of the test material (in distilled water) at 550 mg/kg bw (2 animals) or 2000 mg/kg bw (5 animals), before a 14-day observation period. Animals were checked for clinical signs of toxicity, and effects on body weight. Rats were subject to gross necropsy upon death or terminal killing. Two of the five animals treated with 2000 mg/kg bw died, while neither of the two animals treated with 550 mg/kg bw died. Under the conditions of this study, the acute oral LD50 was estimated to be about 2000 mg/kg bw in female rats. Based on the results of this acute oral rat study, palladium di(4-oxopen-2-en-2-oate) should cautiously be classified for acute oral toxicity (category 4) according to EU CLP criteria (EC 1272/2008).
In a limit test performed in accordance with OECD Test Guideline 402 and to GLP, young Wistar rats (5/sex) were given a 24-hour semi-occlusive application of palladium di(4-oxopen-2-en-2-oate) at 2000 mg/kg bw (dampened with water to ensure good contact with the skin). Animals were observed for 14 days after treatment for deaths, as well as changes in body weight and clinical signs of toxicity. At necropsy, any gross abnormalities were reported. No deaths were seen over the 14-day observation period; the acute dermal LD50 was determined to be more than 2000 mg/kg bw (Matting, 2014). Based on the results of this study, classification for acute dermal toxicity under the EU CLP regulation is not required.
No relevant acute inhalation toxicity data were identified. However, the compound is not expected to reach the lungs in appreciable quantities (based on respiratory tract deposition modelling data). Thus, inhalation will not be a significant route of exposure.
Justification for selection of acute toxicity – oral endpoint
OECD guideline study, to GLP, and the only acute oral toxicity study available
Justification for selection of acute toxicity – dermal endpoint
OECD guideline study, to GLP, and the only acute dermal toxicity study available
Justification for classification or non-classification
Based on the results of the available acute oral rat study, palladium di(4-oxopent-2-en-2-oate) should be classified for acute oral toxicity (category 4) according to EU CLP criteria (EC 1272/2008).
No classification for acute dermal toxicity is required, based on the results of the available and reliable acute dermal rat study with palladium di(4-oxopent-2-en-2-oate).
No clear evidence of specific target organ toxicity was noted. As such, classification for STOT-SE is not considered appropriate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.